Latarcin-3a (5-17) [M5,13L; A6I; E14K; K17I]

General Information


DRACP ID  DRACP04463

Peptide Name   Latarcin-3a (5-17) [M5,13L; A6I; E14K; K17I]

Sequence  LIKKLKEYLKKLI

Sequence Length  13

UniProt ID  Q1ELU3 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C80H144N18O17

Absent amino acids  ACDFGHMNPQRSTVW

Common amino acids  K

Mass  184437

Pl  10.7

Basic residues  5

Acidic residues  1

Hydrophobic residues  6

Net charge  4

Boman Index  -518

Hydrophobicity  -0.77

Aliphatic Index  180

Half Life 
  Mammalian: 5.5 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  1490

Absorbance 280nm  124.17

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 36212827

Title  First generation of multifunctional peptides derived from latarcin-3a from聽Lachesana tarabaevi聽spider toxin

Doi Not available

Year  2022

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  20023

DRACP is developed by Dr.Zheng's team.